Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 17, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral...
-
Feb 14, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release financial results for its fourth quarter and calendar year 2016 on Monday, February 27, 2017 at approximately 4:00 p.m....
-
Feb 7, 2017
Perrigo Company plc (NYSE; TASE: PRGO) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for clindamycin, benzoyl peroxide...
-
Feb 7, 2017Company to Reconstitute Board with Five New Independent Directors
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has entered into an agreement with Starboard Value LP ("Starboard"), which owns approximately 6.7 percent of Perrigo's shares,...
-
Jan 24, 2017
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received U.S. Food and Drug Administration approval for its first-to-file Abbreviated New Drug Application referencing Taro...
-
Jan 10, 2017
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has changed its reporting segments to better align with the Company's organizational structure. Beginning with the fourth quarter of...
-
Dec 22, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced that CEO John T. Hendrickson will present at the J.P. Morgan Global Healthcare Conference at 11:00 AM EST on Tuesday, January 10, 2017 at the...
-
Dec 20, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received approvals from the U.S. Food and Drug Administration for Abbreviated New Drug Applications referencing GlaxoSmithKline's...
-
Dec 8, 2016
Perrigo Company plc (NYSE: PRGO; TASE) today announced its intention to restructure the Branded Consumer Healthcare's ("BCH") Omega Pharma Belgium business (which includes Omega Pharma Belgium NV,...
-
Nov 10, 2016
Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses* Delivered...